Loxenatide plus LNG-IUS combination therapy aims to improve endometrial atypical hyperplasia response rates

Endometrial atypical hyperplasia (EAH) is a precursor to endometrial cancer, with obesity being a significant risk factor, increasing surgical complexity and morbidity. Current standard-of-care often involves hysterectomy, but this is not ideal for all patients, especially those desiring fertility preservation or with severe comorbidities. Levonorgestrel-releasing intrauterine systems (LNG-IUS) offer a progestin-based, non-surgical option by counteracting estrogen's effects on the endometrium, but response rates can be suboptimal. Exploring adjunct therapies like GLP-1 agonists could enhance efficacy.

This phase II clinical trial is designed to evaluate the efficacy of polyethylene glycol loxenatide in combination with a levonorgestrel-releasing intrauterine system (LNG-IUS). The study will enroll patients diagnosed with endometrial atypical hyperplasia. The primary objective is to determine if this combination therapy improves pathologic response rates, defined as the absence of cancer cells in post-treatment tissue samples. The trial aims to identify whether adding the GLP-1 agonist to LNG-IUS enhances therapeutic outcomes for this patient population.

The provided information describes the objective of an ongoing phase II trial rather than presenting completed results. Therefore, no specific findings, statistical data, or quantitative outcomes regarding the efficacy of Loxenatide plus LNG-IUS in improving response rates for endometrial atypical hyperplasia are available in this record. The study aims to determine if this combination therapy will improve response rates, but the actual findings are not yet reported.